Amplia Therapeutics Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INNMF research report →
Companywww.ampliatx.com
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney.
- CEO
- Christopher J. Burns
- IPO
- 2021
- Employees
- 1
- HQ
- Melbourne, VIC, AU
Price Chart
Valuation
- Market Cap
- $56.44M
- P/E
- -7.26
- P/S
- 29.14
- P/B
- 1.34
- EV/EBITDA
- -3.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.60%
- Op Margin
- -452.89%
- Net Margin
- -333.83%
- ROE
- -24.81%
- ROIC
- -18.65%
Growth & Income
- Revenue
- $3.78M · -15.03%
- Net Income
- $-6,572,031 · -45.93%
- EPS
- $-0.02 · 7.76%
- Op Income
- $-6,516,148
- FCF YoY
- -34.28%
Performance & Tape
- 52W High
- $0.27
- 52W Low
- $0.03
- 50D MA
- $0.12
- 200D MA
- $0.10
- Beta
- -0.43
- Avg Volume
- 20.86K
Get TickerSpark's AI analysis on INNMF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our INNMF Coverage
We haven't published any research on INNMF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INNMF Report →